TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
Want to see RNAZ full AI Analyst Report?
Top Page
TransCode Therapeutics
(NASDAQ:RNAZ)
Select Model
Select Model
Rating:49Neutral
Price Target:
$11.50
▲(65.23% Upside)
Action:Reiterated
Date:01/24/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.
Positive Factors
Delivery platform efficacy (glioblastoma preclinical)
Published murine glioblastoma results demonstrate the company’s delivery platform can systemically deliver antisense payloads to brain tumors and extend survival. This durable technical validation strengthens the platform’s differentiation and supports advancing indications beyond metastatic disease.
Negative Factors
No revenue; widening net losses
Persistent zero revenue with expanding net losses means the company lacks internal revenue-derived funding and must rely on external capital. Over months this increases dilution risk, constrains investment choices, and places pressure on program prioritization and long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Delivery platform efficacy (glioblastoma preclinical)
Published murine glioblastoma results demonstrate the company’s delivery platform can systemically deliver antisense payloads to brain tumors and extend survival. This durable technical validation strengthens the platform’s differentiation and supports advancing indications beyond metastatic disease.
Read all positive factors
TransCode Therapeutics (RNAZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.27M
Dividend YieldN/A
Average Volume (3M)282.59K
Price to Earnings (P/E)―
Beta (1Y)2.53
Revenue GrowthN/A
EPS Growth95.40%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding950,302
10 Day Avg. Volume825,542
30 Day Avg. Volume282,592
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-2.05K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit703.98K
Enterprise Value/Ebitda575.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TransCode Therapeutics Business Overview & Revenue Model
Company Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage...
How the Company Makes Money
TransCode Therapeutics primarily generates revenue through the development and potential commercialization of its RNA-based therapeutic candidates. The company may enter into collaborative agreements or partnerships with larger pharmaceutical comp...
TransCode Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.22K | 0.00 | -534.86K | -516.75K | -98.61K | -42.47K |
| EBITDA | -22.28M | -34.31M | -16.19M | -17.97M | -17.47M | -6.71M |
| Net Income | -19.53B | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M |
Balance Sheet | ||||||
| Total Assets | 157.16B | 162.40M | 7.29M | 5.17M | 7.59M | 22.94M |
| Cash, Cash Equivalents and Short-Term Investments | 12.84B | 17.81M | 5.81M | 2.77M | 4.98M | 20.83M |
| Total Debt | 0.00 | 0.00 | 38.29K | 450.57K | 0.00 | 0.00 |
| Total Liabilities | 12.64B | 152.06M | 9.31M | 3.53M | 4.35M | 2.53M |
| Stockholders Equity | 1.25B | 10.34M | -2.02M | 1.64M | 3.24M | 20.40M |
Cash Flow | ||||||
| Free Cash Flow | -4.99B | -19.52M | -13.36M | -18.11M | -15.86M | -5.52M |
| Operating Cash Flow | -4.99B | -19.52M | -13.34M | -18.07M | -15.76M | -5.27M |
| Investing Cash Flow | -4.44K | -4.44K | -21.76K | -35.61K | -100.92K | -251.82K |
| Financing Cash Flow | 22.67M | 31.52M | 16.40M | 15.91M | 5.99K | 25.52M |
TransCode Therapeutics Technical Analysis
Neutral
6.96
Price Trends
9.31
Negative
8.99
Negative
9.94
Negative
Market Momentum
-0.15
Negative
48.33
Neutral
38.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAZ, the sentiment is Neutral. The current price of 6.96 is below the 20-day moving average (MA) of 8.68, below the 50-day MA of 9.31, and below the 200-day MA of 9.94, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 38.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNAZ.
TransCode Therapeutics Risk Analysis
TransCode Therapeutics disclosed 91 risk factors in its most recent earnings report. TransCode Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TransCode Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $14.67M | -0.32 | -189.72% | ― | ― | 80.68% | |
49 Neutral | $6.27M | ― | -684.86% | ― | ― | 95.40% | |
49 Neutral | $11.08M | -0.83 | -32.58% | ― | -100.00% | 13.00% | |
47 Neutral | $22.33M | -1.78 | -74.15% | ― | -24.96% | 46.11% | |
40 Underperform | $1.24M | -1.72 | 1211.14% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
RNAZ
TransCode Therapeutics
6.60
-0.10
-1.49%
KPRX
Kiora Pharmaceuticals
2.50
-0.66
-20.89%
VYNE
VYNE Therapeutics
0.67
-0.55
-45.08%
LYRA
Lyra Therapeutics
0.70
-4.64
-86.89%
INAB
IN8bio
1.49
-2.26
-60.27%
TransCode Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
TransCode Therapeutics reports promising preclinical glioblastoma results
Positive
Jan 6, 2026
On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of Functional Biomaterials of preclinical data showing that its lead RNA-based candidate TTX-MC138 successfully targeted glioblastoma multiforme tumors in murine m...
Business Operations and StrategyExecutive/Board Changes
TransCode Therapeutics Strengthens Board with Veteran Financial Expert
Positive
Dec 22, 2025
On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, designating him an independent director and financial expert with a term running until the 2026 annual meeting. Stover...
Business Operations and StrategyProduct-Related Announcements
TransCode Announces Collaboration for Phase 2a Trial
Positive
Dec 11, 2025
On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead therapeutic candidate, TTX-MC138, in a Phase 2a dose-expansion trial as part of the PRE-I-SPY clinical trial p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.